1. Home
  2. TNET vs IMCR Comparison

TNET vs IMCR Comparison

Compare TNET & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

HOLD

Current Price

$37.06

Market Cap

1.7B

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$30.09

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNET
IMCR
Founded
1988
2008
Country
United States
United Kingdom
Employees
2700
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2000
2016

Fundamental Metrics

Financial Performance
Metric
TNET
IMCR
Price
$37.06
$30.09
Analyst Decision
Hold
Buy
Analyst Count
5
12
Target Price
$65.80
$61.82
AVG Volume (30 Days)
518.7K
358.8K
Earning Date
04-24-2026
05-06-2026
Dividend Yield
2.94%
N/A
EPS Growth
N/A
30.39
EPS
3.20
N/A
Revenue
$5,010,000,000.00
$249,428,000.00
Revenue This Year
N/A
$14.39
Revenue Next Year
$3.30
$8.19
P/E Ratio
$11.69
N/A
Revenue Growth
N/A
43.05
52 Week Low
$33.67
$23.15
52 Week High
$88.56
$40.71

Technical Indicators

Market Signals
Indicator
TNET
IMCR
Relative Strength Index (RSI) 37.49 37.35
Support Level $33.67 N/A
Resistance Level $39.10 $34.86
Average True Range (ATR) 1.62 1.42
MACD 0.82 -0.25
Stochastic Oscillator 48.33 9.81

Price Performance

Historical Comparison
TNET
IMCR

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: